Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dotarem vs Gadavist in Contrast Enhanced Breast MRI
NCT03730051Phase 4Completed
- Sponsor
- University of Massachusetts
- Start
- Mar 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of gadoterate meglumine in Breast disease (2 arms), sponsored by University of Massachusetts. Primary endpoint: Quality of breast MRI at 6 months. Started Mar 2021; status: completed.
02
Drugs
gadoterate meglumine
03
Conditions
Breast disease
Beyond the preview
Go deeper on NCT03730051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03730051.